OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Robson, M Im, S Senkus, E Xu, B Domchek, S Masuda, N Delaloge, S Li, W Tung, N Armstrong, Anne C
Robson, M
Im, S
Senkus, E
Xu, B
Domchek, S
Masuda, N
Delaloge, S
Li, W
Tung, N
Armstrong, Anne C
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Robson ME, Im S-A, Senkus E, Xu B, Domchek S, Masuda N, et al. OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Cancer Res. 2018;78(13).